Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Madrigal Pharmaceuticals Inc
(NQ:
MDGL
)
262.56
+3.75 (+1.45%)
Streaming Delayed Price
Updated: 12:37 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
January 12, 2024
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.
Via
Benzinga
3 Stocks That Could Be Monster Winners in 2024
December 30, 2023
Don't be surprised if these three stocks take off in the new year.
Via
The Motley Fool
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 08, 2023
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.
Via
Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
November 13, 2023
Via
Benzinga
2 Risky Stocks With Massive Potential
October 17, 2023
Neither is doing well this year.
Via
The Motley Fool
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street
September 20, 2023
This company is on the brink of a major breakthrough.
Via
The Motley Fool
These 2 Stocks Could Be About to Soar: Are They Buys?
December 07, 2023
One thing is for certain -- both of these companies are innovators.
Via
The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
November 30, 2023
These stocks just might have investors seeing double over the next few years.
Via
The Motley Fool
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
November 21, 2023
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...
Via
Benzinga
Topics
ETFs
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
November 17, 2023
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.
Via
Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
November 14, 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.
Via
InvestorPlace
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
September 13, 2023
Via
Investor Brand Network
The Latest Analyst Ratings for Madrigal Pharmaceuticals
September 11, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 02, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 19, 2023
Via
Benzinga
Nike, Carnival And 3 Stocks To Watch Heading Into Friday
September 29, 2023
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?
September 28, 2023
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
September 27, 2023
It has a good shot at commercializing a drug to treat a common liver disease.
Via
The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...
Via
Benzinga
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line
September 13, 2023
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures.
Via
Investor's Business Daily
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
September 11, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
August 30, 2023
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months.
Via
InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
August 23, 2023
NASH treatments are projected to be one of the most sought-after indications in the coming years.
Via
The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
August 23, 2023
NASH is a surprisingly common ailment, and the first treatments are on the way.
Via
The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
August 02, 2023
Novo Nordisk received some good news in a recent physician survey.
Via
The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
June 30, 2023
Madrigal is working on gaining FDA approval for what could be the first NASH treatment.
Via
Investor's Business Daily
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
June 28, 2023
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was...
Via
Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 27, 2023
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.